For children whose bodies betray them with uncontrollable movements and sounds, the search for relief has long meant choosing between suffering the condition or enduring the heavy toll of its treatments. A clinical trial presented in Seattle now suggests that ecopipam — a drug that once sought a different purpose — may offer young Tourette patients meaningful relief from tics without the weight gain and mood disruptions that have made existing medications a last resort for so many families. The finding does not close the chapter on this neurological condition, but it may open a door that has b
Experimental drug ecopipam shows 30% tic reduction in Tourette syndrome trials
Children and teens with Tourette syndrome experience repetitive, difficult-to-control motor and vocal tics that impact daily functioning, with current treatments often avoided due to severe side effects.
A medication that helps tics without weight gain or mood changes
Mark
Why does a weight-loss drug failure suddenly matter for Tourette syndrome?
Mimi
Because it works on dopamine in a way nothing else does. The brain chemistry that makes you want to eat less is the same system that's misfiring in Tourette. Sometimes the wrong answer to one question is the right answer to another.
Mark
But 30 percent reduction—is that enough to change a child's life?
Mimi
It depends on where you're starting. If you're a teenager making involuntary sounds in class, 30 percent fewer tics might mean you can actually sit through a lesson. It might mean you go to the cafeteria without feeling watched. The current drugs work better, but they make you gain weight and feel depressed. Parents look at that choice and say no. So 30 percent without those costs becomes the choice that actually gets used.
Mark
Why can't doctors just use cognitive behavioral therapy instead?
Mimi
They want to. It works just as well. But there aren't enough therapists, they're booked for months, and most don't take insurance. You can't prescribe what doesn't exist. A pill you can give on day one matters when therapy is a six-month wait.
Mark
What happens if this gets approved?
Mimi
It becomes another option in the toolbox. Not a replacement for therapy, but a real alternative to the old medications that families have been avoiding. For some kids, that changes everything.
Mark
Is this the end of the story for Tourette treatment?
Mimi
No. This is one drug. The real shift is that researchers are finally looking at dopamine differently, not just borrowing psychiatric medications. There will be others.
O Pulso
- Children with Tourette syndrome face a painful dilemma: leave tics untreated or accept medications borrowed from psychiatry that cause weight gain, depression, and emotional instability.
- In a 149-person trial, ecopipam reduced tic severity by 30% — nearly double the placebo effect — by targeting a dopamine receptor no existing drug has ever touched.
- The side effect profile was strikingly mild, with headache and fatigue as the primary complaints, a sharp contrast to the metabolic and neuropsychiatric burdens of current treatments.
- The preferred alternative — cognitive behavioral therapy — is equally effective but practically out of reach for most families due to specialist shortages, long wait times, and insurance barriers.
- FDA approval is not yet secured and findings await peer review, but clinicians who treat Tourette patients are already calling the research a meaningful and encouraging step forward.
For children whose bodies betray them with uncontrollable movements and sounds, the search for relief has long meant choosing between suffering the condition or enduring the heavy toll of its treatments. A clinical trial presented in Seattle now suggests that ecopipam — a drug that once sought a different purpose — may offer young Tourette patients meaningful relief from tics without the weight gain and mood disruptions that have made existing medications a last resort for so many families. The finding does not close the chapter on this neurological condition, but it may open a door that has been shut for a generation.
A drug that once failed as a weight-loss treatment may have found its true calling in quieting the involuntary tics that define Tourette syndrome in children and teenagers. Presented at the American Academy of Neurology meeting in Seattle, a three-month trial of 149 young people ages 6 to 17 found that ecopipam reduced tic severity by 30 percent — substantially outpacing the 19 percent improvement seen with placebo. Crucially, it did so without the weight gain and mood disturbances that shadow every currently approved Tourette medication.
Tourette syndrome disrupts dopamine signaling in the brain, compelling sufferers to produce movements and sounds — eye blinking, shoulder shrugging, throat clearing — that are exhausting to suppress and socially isolating. Existing treatments like Haldol and Risperdal were originally developed for schizophrenia and carry steep costs: significant weight gain and neuropsychiatric side effects that lead many parents to refuse medication altogether, leaving children to manage on their own.
Ecopipam works differently. It blocks D1 dopamine receptors — a target no existing drug addresses. Lead researcher Dr. Donald Gilbert of Cincinnati Children's Hospital, who has spent over two decades treating Tourette patients, said he would personally choose ecopipam over current options if it were available. Participants on the drug saw their tic severity scores drop dramatically on two separate scales; the most common side effects were headache and fatigue, reported at manageable rates.
Still, ecopipam may not become the first line of treatment. Cognitive behavioral therapy — which trains patients to recognize tic triggers and build control strategies — is considered equally effective and is preferred by specialists. But therapists with this expertise are booked months out, rarely accept insurance, and the approach demands sustained effort from families. For many, medication remains the only realistic path.
Gilbert noted that Tourette symptoms often ease naturally into adulthood, making the childhood and adolescent years the critical window. A medication with fewer side effects could mean the difference between a child receiving help and a child going without. The findings are preliminary pending peer review, but they point toward a future where families may finally have a treatment option that doesn't ask them to trade one burden for another.
A drug that once failed to help people lose weight may have found its true purpose: quieting the involuntary movements and sounds that define Tourette syndrome in children and teenagers.
Ecopipam reduced tic severity by 30 percent in a three-month trial of 149 young people ages 6 to 17, according to research presented at the American Academy of Neurology meeting in Seattle. The improvement substantially outpaced the 19 percent reduction seen in those given a placebo. More importantly, the drug achieved this without the weight gain and mood disturbances that plague every approved Tourette medication currently on the market—a distinction that could reshape how doctors and families approach treatment for a condition that causes repetitive, difficult-to-suppress motor and vocal tics like eye blinking, shoulder shrugging, throat clearing, or involuntary utterances.
Tourette syndrome is a neurological disorder rooted in disrupted dopamine signaling in the brain. The condition forces sufferers to produce movements and sounds they cannot easily control, and the effort to suppress them often exhausts and isolates young patients. Current treatments—Haldol, Risperdal, and Xenazine—were borrowed from psychiatry, originally developed to treat schizophrenia and other mental illnesses. They work, but the cost is steep: significant weight gain and neuropsychiatric side effects including depression and involuntary movements of their own. Many parents, faced with this trade-off, refuse medication altogether, leaving their children to manage tics through willpower alone.
Ecopipam operates through a completely different mechanism. It blocks D1 dopamine receptors—a target no existing drug touches. "There are no drugs on the market for anything that bind to and block that receptor," explained Dr. Donald Gilbert, the lead researcher and a pediatric movement disorders specialist at Cincinnati Children's Hospital. In the trial, participants taking ecopipam saw their average tic severity score drop from 35 to 24 on a 50-point scale. On a separate 100-point measure, the reduction was even steeper: from 68 to 46. The placebo group, by contrast, improved only modestly on both measures. The most common side effect was headache and fatigue, reported by 34 percent of those on ecopipam compared to 21 percent on placebo—a manageable difference.
Gilbert, who has spent more than two decades treating Tourette patients with existing medications, said he would choose ecopipam if given the option. "If I have a choice, having over 20 years of clinical experience with the drugs that are on the market, I would prefer to use this one," he said. The drug is a once-daily pill, with dosing adjusted for a patient's weight. If the FDA approves it, it would represent the first genuinely new approach to Tourette treatment in years.
Yet ecopipam is not a cure-all, and it may not even be the first-line treatment going forward. Dr. Ivan Pavkovic, a pediatric neurologist at Cohen Children's Medical Center in New York who was not involved in the study, noted that cognitive behavioral therapy—which teaches patients to recognize tic triggers and develop control strategies—is equally effective as medication and remains the preferred approach. The problem is access. Therapists specializing in this work are booked months in advance, often do not accept insurance, and the treatment demands sustained commitment from both child and parent. For many families, medication remains the only realistic option.
Gilbert noted that Tourette symptoms often diminish naturally over time, and most adults with the condition do not require ongoing treatment. For the years when symptoms are most disruptive—childhood and adolescence—having a medication with fewer side effects could mean the difference between a child receiving treatment and a child suffering untreated. Pavkovic called the research encouraging. "The exciting thing about this study, as somebody who treats tics, is that people are working on this and coming up with new medications that have fewer side effects," he said. "That's a good thing, any way you look at it." The findings are preliminary until published in a peer-reviewed journal, but they suggest that the next chapter of Tourette treatment may finally offer families a choice that doesn't demand they sacrifice their child's metabolic health or emotional stability.
Citações Notáveis
There are no drugs on the market for anything that bind to and block that receptor. Ecopipam is a medication that, if approved, would be a completely different way of treating tics and other brain problems.— Dr. Donald Gilbert, Cincinnati Children's Hospital
The exciting thing about this study is that people are working on this and coming up with new medications that have fewer side effects. That's a good thing, any way you look at it.— Dr. Ivan Pavkovic, Cohen Children's Medical Center
Quer a matéria completa?
Leia o original em UPI News ↗
Economy & Finance